Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France; Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Laarbeeklaan 101, 1090 Jette, Brussels, Belgium.
Heart Rhythm Management Department, Clinique Pasteur, Toulouse, France.
Int J Cardiol. 2024 Dec 15;417:132522. doi: 10.1016/j.ijcard.2024.132522. Epub 2024 Sep 6.
The role of catheter ablation in elderly patients with atrial fibrillation (AF) is unclear. Pulsed field ablation (PFA) demonstrates a favorable clinical profile, however, data on elderly patients are lacking.
We aimed to assess the safety and efficacy of PFA in the elderly, using data from the EU-PORIA registry.
Periprocedural complications and long-term safety and efficacy outcomes of AF ablation using the pentaspline PFA catheter (Farapulse™) were compared between patients older than 80 years old and their younger counterparts, across seven European centers.
Among the 1233 patients in the registry, 88 (7.1 %) were older than 80 years. Elderly patients were more often females (51.1 % vs 37.8 %, p = 0.01) with a lower median BMI (26.0, IQR:23.5-29.2 vs 26.9, IQR:24.4-30.4 kg/m, p = 0.02), a higher median CHADS-VASc score (4, IQR:3-5 vs 2, IQR:1-3, p < 0.001) and a higher incidence of hypertension (73.9 % vs 52.7 %, p < 0.001). In both groups, most patients had paroxysmal AF (58.0 % vs 60.3 %, p = 0.65). Ablation in the elderly was more frequently performed with minimally interrupted anticoagulation (87.5 % vs 59.7 %, p < 0.001). Despite comparable rates of overall complications (5.7 % vs 3.5 %, p = 0.29), elderly patients had a higher incidence of stroke (2.3 % vs 0.3 %, p = 0.04). At 12 months, major adverse clinical events (4.5 % vs. 2.1 %, p = 0.12) and arrhythmia-free survival (70 % vs 74 %, p = 0.69) were comparable in both groups. None of the recurrence-free elderly patients were on antiarrhythmic drugs at the end of follow-up.
In this real-world cohort, the efficacy of PFA for AF was similar in elderly and younger patients. Despite comparable complication rates, a higher incidence of stroke was observed in the elderly.
在老年心房颤动(AF)患者中,导管消融的作用尚不清楚。脉冲场消融(PFA)显示出良好的临床效果,然而,缺乏关于老年患者的数据。
我们旨在使用 EU-PORIA 登记处的数据评估 PFA 在老年人中的安全性和疗效。
在七个欧洲中心,比较了使用 pentaspline PFA 导管(Farapulse ™)进行 AF 消融的老年患者(年龄> 80 岁)和年轻患者的围手术期并发症和长期安全性和疗效结局。
在登记处的 1233 名患者中,88 名(7.1%)年龄> 80 岁。老年患者中女性比例较高(51.1%比 37.8%,p = 0.01),中位 BMI 较低(26.0,IQR:23.5-29.2 比 26.9,IQR:24.4-30.4 kg/m,p = 0.02),中位 CHADS-VASc 评分较高(4,IQR:3-5 比 2,IQR:1-3,p<0.001),高血压发生率较高(73.9%比 52.7%,p<0.001)。在两组中,大多数患者均为阵发性 AF(58.0%比 60.3%,p=0.65)。在老年人中,抗凝治疗中断时间更短(87.5%比 59.7%,p<0.001)。尽管总并发症发生率相似(5.7%比 3.5%,p=0.29),但老年患者中风发生率较高(2.3%比 0.3%,p=0.04)。12 个月时,两组主要不良临床事件(4.5%比 2.1%,p=0.12)和无心律失常生存率(70%比 74%,p=0.69)相似。在随访结束时,无复发的老年患者均未服用抗心律失常药物。
在本真实世界队列中,PFA 治疗 AF 在老年患者和年轻患者中的疗效相似。尽管并发症发生率相似,但老年患者中风发生率较高。